Recognize, Diagnose, and Treat Cardiac Amyloidosis

Released On
November 30, 2021

Expires On
November 30, 2022

Media Type

Completion Time
60 minutes


Cardiovascular Disease, Oncology, Radiology

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by The France Foundation and the International Cardio-Oncology Society .


Supported by an educational grant from Eidos Therapeutics Inc.; Pfizer Inc.; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of the cardiology and oncology healthcare teams who treat patients with cardiac amyloidosis, including physicians (cardiologists and hematologists/oncologists) and advance practice providers (nurse practitioners and PAs).

Program Overview

This activity will educate learners about cardiac amyloidosis and the importance of early multidisciplinary diagnosis and management so patients can have the best possible outcomes.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Diagnose cardiac amyloidosis in a timely fashion
  • Describe current and emerging therapies to manage cardiac amyloidosis
  • Develop an effective treatment strategy to manage cardiac amyloidosis
  • Explain the impact of cardiac amyloidosis heterogeneity on the need for multidisciplinary diagnosis + management



Daniel Lenihan, MD


Daniel Lenihan, MD, (Moderator) is president of the International Cardio-Oncology Society. He has extensive experience in the optimal treatment and identification of patients with and at risk for heart failure and other cardiovascular adverse events during and after cancer therapy. He has developed cardio-oncology clinical and research programs in several major institutions over the past 20 years. In addition, he has extensive experience in detecting cardiac related toxicity during cancer therapy and has great interest in cancer survivorship issues relating to cardiac diseases. His research has included multiple studies of growth factors in cardiac disease that have overlap with oncology patients and their treatment. He also has a keen interest in the newly developing diagnostic and treatment choices for patients with amyloidosis. Dr. Lenihan received his MD from the University of Tennessee School of Medicine and completed post-graduate training in internal medicine at Wright-Patterson Air Force Base. He subsequently completed a cardiology fellowship at the University of Cincinnati. He is board certified in Internal Medicine, Cardiology, Advanced Heart Failure/Transplantation, and Cardio-Oncology. He has published over 200 peer reviewed articles, including original research, comprehensive reviews, primers on clinical practice, and more than 10 major book chapters. Dr. Lenihan has been a leading member of many guideline based committees and working groups in a host of professional societies, including the American College of Cardiology, European Society of Cardiology, American Society of Clinical Oncology, European Society of Medical Oncology, and the National Comprehensive Cancer Network. He has been intimately involved in the genesis and growth of the International Cardio-Oncology Society. Dr. Lenihan has been a principal investigator in over 30 clinical research trials and the original author of 3 major clinical trials that have been completed or are nearing completion.

Kathleen Zhang, MD


Kathleen Zhang, MD, completed medical school and Internal Medicine residency at the University of Pennsylvania, followed by fellowships in Cardiology and Cardio-Oncology at Washington University in St. Louis. She specializes in the cardiovascular care of patients with cancer as well as cardiac amyloidosis at Washington University in St. Louis. She has published over 20 peer-reviewed manuscripts in these areas, and served as an editor for the first edition of The Washington Manual of Cardio-Oncology. She is passionate about improving the diagnosis and treatment of patients with cardiac amyloidosis.


Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and the International Cardio-Oncology Society. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosures of Conflicts of Interest

Faculty Disclosures - Activity Faculty

The faculty listed below report that they have no relevant financial relationships to disclose:
  • Daniel Lenihan, MD
Katie Zhang, MD
  • Advisory Board : Eidos Therapeutics

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures
  2. Participate in the online activity
  3. Submit the evaluation form
Certificates will be emailed to the participant

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

The France Foundation (TFF) and the International Cardio-Oncology Society (IC-OS) require that CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and IC-SO do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.


The France Foundation and International Cardio-Oncology Society present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, International Cardio-Oncology Society, and the commercial supporter assume no liability for the information herein.

Contact Information

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or